1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The link for this program now points to a previous cycle.
Historical funding: Varies
Prior eligibility: Small U. S. -based businesses developing quantum-based technologies for biomedical applications.
NIH Quantum Sensing in Biomedical Applications (SBIR/STTR) is a grant from NIH that funds small businesses developing quantum sensing technologies for biomedical and clinical research. Issued as a Notice of Special Interest (NOSI NOT-EY-24-014), the program is supported by NEI, NHLBI, NIBIB, NCATS, and NCI. Areas of interest include quantum imaging and sensing devices, portable quantum sensors for in vivo diagnostics, lab-on-a-chip systems, and quantum-classical computational tools for drug discovery and disease detection. Phase I SBIR applicants typically receive up to ,000 for feasibility work. Applications are accepted through January 27, 2027, using NIH parent SBIR/STTR solicitations.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article